These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8566000)

  • 1. Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem.
    Miró E; Navarro F; March F; Sanchez F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 1995 Aug; 14(8):731-2. PubMed ID: 8566000
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa.
    Başustaoğlu AC; Gün H; Saraçli MA; Baysallar M; Haznedaroğlu T
    Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):469-70. PubMed ID: 7556242
    [No Abstract]   [Full Text] [Related]  

  • 3. A Child With Septic Shock and Purpura.
    Flinn A; McDermott M; Butler KM
    JAMA Pediatr; 2016 Apr; 170(4):391-2. PubMed ID: 27043666
    [No Abstract]   [Full Text] [Related]  

  • 4. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns.
    Troillet N; Samore MH; Carmeli Y
    Clin Infect Dis; 1997 Nov; 25(5):1094-8. PubMed ID: 9402364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological and epidemiological characterization of imipenem-resistant Pseudomonas aeruginosa strains from a Brazilian tertiary hospital: report from the SENTRY Antimicrobial Surveillance Program.
    Ribeiro J; Mendes RE; Domingos R; França E; Silbert S; Jones RN; Sader HS
    J Chemother; 2006 Oct; 18(5):461-7. PubMed ID: 17127220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa.
    Lepper PM; Grusa E; Reichl H; Högel J; Trautmann M
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2920-5. PubMed ID: 12183248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of resistance in imipenem therapy in Pseudomonas aeruginosa].
    Krech T; Naumann P
    Immun Infekt; 1986 Nov; 14(6):224-6. PubMed ID: 3100426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of imipenem against Pseudomonas and Bacteroides species.
    Williams JD
    Rev Infect Dis; 1985; 7 Suppl 3():S411-6. PubMed ID: 3931197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome.
    Krcméry V; Trupl J; Kunová A; Spánik S; Ilavská I; Hel'pianska L; Bezáková I; Drgona L; Oravcová E; Studená M; Lacka J; Sevcíková L; Koren P; Kukucková E; Stopková K; Krupová I; Grausová S; Svec J
    Bratisl Lek Listy; 1996 Nov; 97(11):647-51. PubMed ID: 9117427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa.
    Matsumoto T; Kumazawa J; Nagayama A
    J Antimicrob Chemother; 1996 Aug; 38(2):322-4. PubMed ID: 8877553
    [No Abstract]   [Full Text] [Related]  

  • 13. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
    Hikida M; Yamazaki Y; Yoshida M; Kawashima K; Nishiki K; Mitsuhashi S
    J Antibiot (Tokyo); 1995 Aug; 48(8):891-2. PubMed ID: 7592037
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selection of resistant variants by broad spectrum beta-lactam antibiotics: to what extent is there cross resistance between imipenem and other beta-lactam antibiotics?].
    Kahan F; Kropp H
    Immun Infekt; 1986 Nov; 14(6):232-5. PubMed ID: 3100429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance of Pseudomonas aeruginosa to killing by ciprofloxacin, gentamicin and imipenem in vitro and in vivo.
    Davey P; Barza M; Stuart M
    J Antimicrob Chemother; 1988 Apr; 21(4):395-404. PubMed ID: 3132439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of ciprofloxacin-resistant pseudomonas in pediatric otitis media.
    Jang CH; Park SY
    Int J Pediatr Otorhinolaryngol; 2003 Apr; 67(4):313-6. PubMed ID: 12663100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms.
    Quinn JP; Studemeister AE; DiVincenzo CA; Lerner SA
    Rev Infect Dis; 1988; 10(4):892-8. PubMed ID: 3142013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
    Jang CH; Park SY
    Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):321-3. PubMed ID: 15270816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.
    Jung R; Fish DN; Obritsch MD; MacLaren R
    J Hosp Infect; 2004 Jun; 57(2):105-11. PubMed ID: 15183239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.